drugset
drugset / Trial / NCT04442945

Phase 1 Study of ANAVEX3-71

NCT04442945 ↗

Phase 1 Completed 36 enrolled Anavex Life Sciences Corp. Anavex Australia Pty Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A first in human phase 1 study in healthy volunteers to assess ANAVEX3-71 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics

Timeline

Start
2020-07-03
Primary completion
2021-09-30
Completion
2021-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ANAVEX3-71 Unknown — Oral

Indications

No indication recorded.